Influence of Training Session Duration on Improvements in Physiological Resilience to Exercise (RED)

April 9, 2026 updated by: Centre Hospitalier Universitaire de Saint Etienne
During prolonged endurance exercise, certain physiological variables deteriorate depending on the duration of the exercise. Physiological resilience has therefore been defined as the ability to resist these changes and appears to be an important performance factor in endurance sports. For example, most studies in this field have investigated changes in cycling power output associated with the first ventilatory threshold (VT1), a marker of an individual's endurance capacity, after prolonged endurance exercise. To date, only two studies have examined the effects of training on resilience. The first compared the effectiveness of two training programs, one with low-intensity sessions and the other with high-intensity sessions, with no difference between the conditions. The second study showed that incorporating strength training into a running training program was more effective at improving resilience than running alone. However, the influence of training session duration on resilience remains unknown. Only one observational study has shown that in a group of runners of similar ability, those who were used to doing long sessions had better resilience than those who only did short sessions.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

We hypothesize that at equal intensity and volume, a less frequent training consisting of long sessions would be more effective in improving physiological resilience than a more frequent training composed of short sessions.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
40

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • France
      • Saint-Etienne, France, 42055

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Subjects who engage in rigorous cardiovascular activity (e.g., endurance sports, team sports, combat sports, etc.) for a maximum of two hours per week
  • Ability to understand, speak, read, and write French
  • Affiliated with or beneficiaries of a social security system
  • Having freely given their written consent after being informed of the purpose, procedure, and potential risks involved

Exclusion Criteria:

  • Subjects with chronic joint conditions (e.g., recurrent sprains, patellar or ligament problems).
  • Subjects with one or more heart conditions, including ischemic, valvular, arrhythmic, hypertensive, congenital, or hypertrophic heart disease.
  • Participants under guardianship or conservatorship.
  • Subjects with chronic or central neurological conditions.
  • Subjects who report having taken products prohibited by the World Anti-Doping Agency.
  • Pregnant or breastfeeding women.
  • Subjects who are unable to understand the purpose and conditions of the study and unable to give their consent.
  • Persons deprived of their liberty by judicial or administrative decision, persons receiving psychiatric care under Articles L. 3212-1 and L. 3213-1 who are not covered by the provisions of Article L. 1121-8, and persons admitted to a health or social care facility for purposes other than research.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Long sessions group
Group benefiting from long sessions, twice a week
Other: Long sessions
Training frequency of 2 long sessions per week
Active Comparator: Short sessions group
Group benefiting from short sessions, 5 times a week
Other: Short sessions
Training frequency of 5 short sessions per week

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Power (watt) output at ventilatory threshold 1 (VT1)
Time Frame: At inclusion, Day 80.
the power (Watt) output at the VT1 measured by the difference of the power output (% decrease after 4 hours of cycling) between measurements taken before and after a training program. The results will be compared between group benefiting from long sessions and group from short sessions
At inclusion, Day 80.

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
a) Degree of change in heart rate (beats per minute),
Time Frame: Day 7, Day 85
Degree of changes in heart rate (beats per minute) during a 4-hour endurance cycling session, as measured by a heart rate monitor. The results will be compared between group benefiting from long sessions and group from short sessions
Day 7, Day 85
Rate of change in oxygen consumption (in L of O₂/min)
Time Frame: Day 7, Day 85
the rate of change in oxygen consumption (in L O₂/min) during a prolonged 4-hour endurance cycling exercise, quantified by measuring gas exchange (calculated using the equations of Jeukendrup and Wallis). The results will be compared between group benefiting from long sessions and group from short sessions
Day 7, Day 85
b) The Power (watt) output at ventilatory threshold 2 (VT2)
Time Frame: At inclusion, Day 80.
the power (Watt) output at the VT2 measured by the difference of the power output (% decrease after 4 hours of cycling) between measurements taken before and after a training program. The results will be compared between group benefiting from long sessions and group from short sessions
At inclusion, Day 80.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Centre Hospitalier Universitaire de Saint Etienne

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Léonard FEASSON, PHD, CHU de Saint-Etienne

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
April 8, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
November 15, 2028

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
February 28, 2029

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
March 25, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 25, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
March 31, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
April 14, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 9, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
April 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 25CH281
  • ANSM (Other Identifier: 2024-A02435-42)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings